Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ITPR1 | Q14643 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29441770 | 0.87 | KMT2A (1.00) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL29385360 | 0.87 | KMT2A (1.00) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL113945 | 0.87 | KMT2A (1.00) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL19876090 | 0.85 | KMT2A (0.97) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL27758819 | 0.85 | KMT2A (0.97) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL27740724 | 0.85 | KMT2A (0.97) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL10906640 | 0.84 | KMT2A (0.94) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| Succinimide SCHEMBL28533920 | 0.84 | KMT2A (0.77) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL591648 | 0.83 | KMT2A (0.91) | KMT2AMEN1KDM4ECYP1A2CYP2D6 | |
| SCHEMBL8644297 | 0.83 | KMT2A (0.91) | KMT2AMEN1KDM4ECYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108026575-B | Method for amplifying nucleic acid sequence | 哈佛学院董事及会员团体 | 2022-08-19 | — | — | CN | disclosed |
| US-11121176-B2 | Nearly 2D electronic microparticles | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-09-14 | — | — | US | disclosed |
| US-11078412-B2 | Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence | SHIMADZU CORPORATION (JP) | 2021-08-03 | — | — | US | disclosed |
| CN-111081476-B | Biological photovoltaic cell and preparation method thereof | 中国科学院化学研究所 | 2021-07-20 | — | — | CN | disclosed |
| CN-111081476-A | Biological photovoltaic cell and preparation method thereof | 中国科学院化学研究所 | 2020-04-28 | — | — | CN | disclosed |
| US-20180051205-A1 | FLUORESCENCE DERIVATIZATION REAGENT AND AMINE ANALYSIS METHOD | SHIZUOKA PREFECTURE PUBLIC UNIVERSITY CORPORATION (JP) | 2018-02-22 | — | — | US | disclosed |
| US-20130183249-A1 | Stimulus Sensitive Magnetic Nanocomposite Using Pyrene Polymer, and Contrast Medium Composition Containing the Nanocomposite | INDUSTRY ACADEMIC COOPERATION FOUNDATION YOUNSEI UNIVERSITY (KR) | 2013-07-18 | — | — | US | disclosed |
| US-20120264108-A1 | Intracellular Molecular Delivery Based On Nanostructure Injectors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-10-18 | — | — | US | disclosed |
| US-7235650-B2 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7223833-B1 | Peptide nucleic acid conjugates | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-29 | — | — | US | disclosed |
| EP-0724447-B1 | DERIVATIZED OLIGONUCLEOTIDES HAVING IMPROVED UPTAKE | ISIS PHARMACEUTICALS INC (US) | 2003-05-07 | — | — | EP | disclosed |
| US-20030064492-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| US-20020177150-A1 | Derivatized oligonucleotides having improved uptake and other properties | ISIS PHARMACEUTICAL, INC. | 2002-11-28 | — | — | US | disclosed |
| EP-0804456-B1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2002-08-21 | — | — | EP | disclosed |
| US-6395492-B1 | MONITORING CELLULAR INTAKE OF ADJUSTED NUCLEOSIDES; OBTAIN ORGANISM, INCUBATE WITH ADJUSTED NUCLEOSIDES, MONITOR CELL FOR REPORTER SIGNAL, PRESENCE INDICATES INTAKE | ISIS PHARMACEUTICALS, INC. | 2002-05-28 | — | — | US | disclosed |
| US-6153737-A | OLIGONUCLEOTIDES HAVING IMPROVED TRANSFER ACROSS CELLULAR MEMBRANES; FOR ASSAYING DISEASE STATES IN ANIMALS; HAVING IMPROVED TRANSFER AND UPTAKE PROPERTIES FOR TREATMENT OF DISEASES THROUGH MODULATION OF ACTIVITY OF DNA AND RNA | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| EP-0804456-A4 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 1999-05-19 | — | — | EP | disclosed |
| EP-0804456-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1996011205-A9 | PEPTIDE NUCLEIC ACID CONJUGATES | — | 1996-05-30 | — | — | WO | disclosed |
| WO-1996011205-A1 | PEPTIDE NUCLEIC ACID CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078412-B2 | Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence | SRM, PNMT, TH | KMT2A 1393/4885MEN1 2818/4885KDM4E 1794/4885 |
| US-20180051205-A1 | FLUORESCENCE DERIVATIZATION REAGENT AND AMINE ANALYSIS METHOD | PNMT, SRM, PAH | KMT2A 483/4885MEN1 2602/4885KDM4E 773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.